

Quality Indicators: Instances of inappropriate prescribing (overuse, misuse, underuse) in Belgian geriatric divisions (PIP)

Nele Van den Noortgate, Benoit Boland, Jean-Claude Lemper, Pascal Meeus
Expert: Olivia Dalleur
on behalf of the College for Geriatric Medicine

Background

- Inappropriate prescribing (PIP) is a frequent problem in older patients.
- IP should be detected and solved in older patients hospitalized in geriatric medicine
- The STOPP & START.v1 lists (2008) provide clinicians with explicit criteria for, respectively, over/misuse & underuse
- The college for geriatric medicine aims at improving quality of care in geriatric units
- INAMI/RIZIV collects data on medications prescribed during hospital stays

Study Aim

- To identify the prevalence of specific potentially IP (PIP) cases in the geriatric divisions of the Belgian hospitals in 2013 (both clinically relevant, and technically detectable using the INAMI/RIZIV data)

Time-line

1. Selection of inappropriate drug lists (college : 2/2015)
2. Selection of indicators (college : 2/2015)
3. Identification of the codes (team : 2/2015)
4. Protocole (team : 2/2015)
5. Methodological decisions (college 3/2015 & 4/2015)
 - a. Unit of analysis : hospital stay in geriatric unit only
 - b. Exclusion criteria:
 - i. patients with multiples units during one hospital stay
 - ii. patients with < 75 years of age
 - iii. patients with stays \leq 9 days ; and « non-G » stays)
 - iv. patients with strong opioids during last 6 days (to exclude dying patients)

Methods

- Design : cross-sectional study in all geriatric hospital units in Belgium
- Patients : all patients discharged from a geriatric unit in 2013.
- Exclusion criteria
 - patients with multiples units during one hospital stay
 - patients with < 75 years of age
 - patients with stays ≤ 9 days ; and « non-G » stays)
 - patients with strong opioids during last 6 days (to exclude dying patients)
- Starting from the STOPP-START vs 1, 13 PIP were selected. After practical considerations like clinically relevant and technically detectable, the use of 11 drugs at discharge of the patients are described. From those 9 are linked to frequently over- or misused drugs and 2 are linked to frequently underused drugs.
 - 9 frequently over/misused drugs (any prescription during the last 6 days of the G stay)
 - NSAID
 - PPI
 - TCA
 - SSRI
 - Benzodiazepine
 - Antipsychotics
 - Anticholinergic
 - Statin (not in STOPP.v1)
 - Antibiotic during the stay (out of STOPP scope)
 - + **Global indicator** for neuropsych drugs as TCA , BZD , antipsychotics , SSRI
 - 2 frequently underused drugs (any prescription during the G stay)
 - Oral anticoagulant [should be as high as AFib prevalence]
 - Vitamin D [should be as high as osteoporosis,
- Denominators : ALL discharged patients
- Numerators: number of patients with the drug class (ATC code)

Analyses :

- Overall (n=45.086 G stays)
- by Province,
- by Hospital,
- by Patient's characteristics (age, gender)

College criteria adapted from STOPP-START vs1	Indicator in G units	NUMERATOR	DENOMINATOR
1. Global indicator neuropsych drugs TCA, BZD, antipsychotics, SSRI	PIP Over/misuse at end of stay (last 6 days): % with any of the following at discharge (TCA, BZD, antipsychotics and SSRI) at discharge	TCA, BZD, antipsychotics, SSRI	All patients at discharge
2.NSAID	PIP Over/misuse at end of stay (last 6 days): % with NSAIDS at discharge	M01A (ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STERIODS)	All patients at discharge
3. PPI at treatment dose for peptic ulcer disease at full therapeutic dosage for > 8 weeks	PIP Over/misuse at end of stay (last 6 days): % with PPI at discharge	A02BC	All patients at discharge
4. TCA with dementia [risk of worsening cognition]	PIP Over/misuse at end of stay (last 6 days): % of patients on TCAs at discharge	N06AA (tricyclic antidepressant: TCAs)	All patients at discharge
5. BZD (benzodiazepines) if long-term (i.e. > 1 month) and long-acting e.g. chlordiazepoxide, flurazepam, nitrazepam and benzodiazepines with long-acting metabolites e.g. diazepam [risk of prolonged sedation, confusion, impaired balance, falls].	PIP Over/misuse at end of stay (last 6 days): % of patients on benzo at discharge	N05CD (benzo) or N05BA (benzo)	All patients at discharge
6. Antipsychotics	PIP Over/misuse at end of stay (last 6 days): % of patients on antipsychotics at discharge	N05A (antipsychotics)	All patients at discharge
7. SSRI's	Use at end of stay (last 6 days): % of patients on SSRI's at discharge	N06AB (SSRI)	All patients at discharge
8 Anticholinergic drugs	PIP Over/misuse at end of stay (last 6 days): % with score 3 at discharge (see burden scale: score >3) Amitryptiline - TCA Doxepin and others related to TCA	N06AA (Non-sel monoamine reupt. inh) N06AB05 (paroxetine-SSRI) R06AB04 (chlorphenamine) R06A (antihistamines, systemic use) N05CM (other hypnotics, inclusive scopolamine: N05CM05)	All patients at discharge

	Paroxetine Chlorphenamine and sedating antihistamins Hyoscine Olanzapine and other atypicals Oxybutinine	N05AH (diazepine) within N05AH03 (olanzapine) G04BD04 (oxybutynin)	
9.OAC (oral anticoagulant)	PIP Usual UNDERUSE during the stay: % with oral anticoagulant. (VKA or NOAC) during the stay (because UNDERUSE)	B01AA (vitamin K antagonists) Or NOAC, especially B01AE07 (dabigatran) B01AX06 (rivaxoxaban)	All patients during stay
10. vitamin D	PIP Usual UNDERUSE during the stay % patients with vit D during the stay (because UNDERUSE)	A11CB (vit A and D in combination), A11CC (vit D and analogues)) or A12AX (vit D+calcium)	All patients during stay

Feedback to the G units

Feedback to the Geriatric Departments

Through the secretary of the Belgian Society with support of FOD/INAMI

Full file on the website

Invoice to the heads of G wards of the anonymised results with contact point to obtain their own identification number

The college will provide in 2016 a voluntary, non anonymised questionnaire to ask for feedback on the proposed QI and to ask which actions are planned for improvement

LOK/GLEM coordinators are asked to be present at a meeting with the college on november the 17. Information will be given regarding the development and interpretation of the Quality Indicator.

Some examples of discussion points could be offered:

- Role of equipment /infrastructure /organization/ contextual :
 - o staff : FTE geriatricians
 - o presence (and task) of clinical pharmacists
 - o E prescription
 - o Active Role /influence of CMP/MFC (conseil médicopharmaceutique ; medisch farmaceutisch comité)
 - o Care pathway for drug prescription and revision policy...
- Rational use of drugs :
 - o Existing guidelines
 - o Specific strategy on stop and start
 - o Drug prescription revision policy
 - o
- What do you plan to do with those results?
 - o Information session
 - o Adapt general / specific policy
 - o Prescription review
 - o